Form 4: NIKA Pharmaceuticals CEO Dimitar Savov Acquires 2,000,000 Shares
SEC Form 4
Dimitar Slavchev Savov, CEO, CFO, and President of NIKA Pharmaceuticals, purchased 2,000,000 shares of common stock at $0.25 per share on March 18, 2025.
Summary
- On March 18, 2025, Dimitar Slavchev Savov, the CEO, CFO, and President of NIKA Pharmaceuticals, acquired 2,000,000 shares of the company's common stock.
- The purchase price was $0.25 per share.
- Following this transaction, Savov directly owns 455,589,500 shares of NIKA Pharmaceuticals.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of a transaction. The CEO buying shares is generally a positive sign, but without more context, it's difficult to gauge the overall impact.
Positives
- The CEO's purchase of a significant number of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. This allows investors to track the actions of key personnel and assess their confidence in the company.
Stakeholder Impact
- Shareholders may view the CEO's purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 03/18/2025 | Date of stock transaction |
| 03/19/2025 | Date of Form 4 signature |
Keywords
NIKA Pharmaceuticals, Dimitar Slavchev Savov, stock acquisition, Form 4, beneficial ownership, CEO, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.